long-term effects of glp-1 receptor agonists The cardiovascular beyond obesity and type 2 diabetes: An anti-atherosclerotic action Frontiers | GLP-1 Receptor Agonists:

Comparative analysis of cancer risk among glucose-lowering agents Current clinical evidence indicates that various classes of antidiabetic drugs show substantial variability in their association with cancer risk

Its important to emphasize that GLP-1 weight loss drugs are meant to be used in tandem with regular exercise and a healthy diet

In trials, exenatide improved post-meal glucose spikes (due to its gastric slowing effect and insulin boost after meals) and also moderately lowered fasting glucose

Breast Cancer Outcomes and Study Limits In sum, GLP-1RAs were associated with improved all-cause mortality and RFS among adult female BC patients with obesity compared with non-use, and among those with T2D compared with insulin/metformin, while comparisons with SGLT2 inhibitors were less consistent

=0.015)

By weeks two and three, GIP receptor effects become more pronounced